Changes in Medical Privacy Rules Enacted

Publication
Article
OncologyONCOLOGY Vol 16 No 5
Volume 16
Issue 5

President Bush announced changes in the medical records privacy rule proposed by President Bill Clinton before he left office. Physicians do not have to comply with these rules until 2003.

President Bush announced changes in the medical recordsprivacy rule proposed by President Bill Clinton before he left office.Physicians do not have to comply with these rules until 2003. 

One major changeBush made was to specify that physicians and hospitals could, for the purposesof treatment, share medical information about patients with other physicians,hospitals, and providers, and provide medical services to the patientsthemselves, without prior consent. Rather, doctors and other health-careproviders must notify patients of privacy policies and make a "good faitheffort" to get written acknowledgment. 

Physicians had also been concernedabout the provision limiting the use of personal health information to the"minimum necessary." Doctors, patients, nurses, and others involved ina patient’s care feared that routine conversations could violate the rule. TheBush version would continue to cover oral communications and maintain the"minimum necessary" requirement, but would specify that doctors coulddiscuss a patient’s treatment with other professionals without the fear thattheir conversations could lead to a violation. As long as minimum necessarystandards are met and reasonable safeguards are taken to protect personal healthinformation, incidental disclosures would not be subject to penalties.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.